Table 2.
Showing Follow-up Events of Patients on SBP Prophylaxis.
| Events on follow-up | Primary Prophylaxis | Secondary Prophylaxis | ||||
|---|---|---|---|---|---|---|
| Rifaximin n = 28 | Norfloxacin n = 29 | P-value | Rifaximin n = 26 | Norfloxacin n = 33 | P-value | |
| SBP | 4 (14%) | 7 (24%) | 0.55 | 2 (7%) | 13 (39%) | 0.004 |
| HE | 9 (32.1%) | 10 (34.5%) | 0.81 | 6 (23.1%) | 17 (51.5%) | 0.02 |
| AKI | 5 (17%) | 7 (24%) | 0.51 | 4 (15.4%) | 9 (27%) | 0.35 |
| VH | 3 (10.7%) | 3 (10.3%) | 1 | 4 (15.4%) | 1 (3%) | 0.15 |
| Mortality | 8 (28.6%) | 6 (20.74%) | 0.49 | 7 (28.6%) | 12 (26.9%) | 0.27 |
SBP, Spontaneous bacterial peritonitis; HE, Hepatic encephalopathy; AKI, Acute Kidney Injury; VH, Variceal hemorrhage.